AstraZeneca sets up new headquarters in Cambridge

18th Jun 2013 13:07

Pharmaceutical company AstraZeneca is launching its global headquarters at the Cambridge Biomedical Campus. The research and development(R&D) site, which is expected to be open by 2016, is a £330m project. It will replace R&D at Alderley Park in Cheshire which will cease operations. The company is also closing its London headquarters.The group is axing about 700 jobs as part of the closures while other employees are being transferred to the new headquarters.The Cambridge site will become the firm's biggest centre for cancer research and will also cover cardiovascular, metabolic, respiratory, inflammation and autoimmune disease research.AstraZeneca chief executive Pascal Soriot said: "Moving to the Cambridge Biomedical Campus means our people will be able to rub shoulders with some of the world's best scientists and clinicians carrying out some of the world's leading research."RD